Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study

NCT05518201 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05518201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05518201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Safety and Immunogenicity of the 9-valent Human Papillomavirus Recombinant Vaccine (Hansenula Polymorpha) in Chinese Male Aged 9-45 Years: A Randomized, Blinded and Placebo-Controlled Phase I Study
Lead sponsor
Shanghai Bovax Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 23, 2022
Completion date
November 20, 2023
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ain1, ain2, ain3, anal cancer, genital wart, penile cancer, pin-1, pin-2, pin-3